Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 4/20 | 0.32 |
| ▸ | NOS3 | P29474 | 3/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16247669 | 0.86 | DGAT1 (0.39) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL2888150 | 0.80 | DGAT1 (0.41) | DGAT1SRCTEKPDE10ANPC1 | |
| SCHEMBL29854683 | 0.74 | DGAT1 (0.38) | DGAT1PDE10A | |
| SCHEMBL2693867 | 0.74 | DGAT1 (0.38) | DGAT1PDE10A | |
| SCHEMBL20422628 | 0.74 | DGAT1 (0.43) | DGAT1PDE10A | |
| SCHEMBL29663834 | 0.74 | DGAT1 (0.43) | DGAT1PDE10A | |
| SCHEMBL25302547 | 0.73 | DGAT1 (0.40) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL30295787 | 0.73 | DGAT1 (0.35) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL15667407 | 0.73 | DGAT1 (0.35) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL29854576 | 0.72 | DGAT1 (0.37) | DGAT1EGFRIGF1RSRCFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193210-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160136168-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-9108973-B2 | 3,5-disubstituted alkynylbenzene compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20140343035-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO.,LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136168-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | FGFR1, FGFR3, FGFR4 | DGAT1 1982/4885EGFR 14/4885IGF1R 12/4885 |
| US-20160193210-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | FGFR1, FGFR3, FGFR2 | DGAT1 3331/4885EGFR 31/4885IGF1R 10/4885 |
| US-20140343035-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | NFXL1, ZFX, CXXC5 | DGAT1 2256/4885EGFR 1467/4885IGF1R 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.